Imcheck Therapeutics

ImCheck Therapeutics is designing and developing a new generation of immunotherapy antibodies targeting butyrophilins to achieve greater therapeutic efficacy than the first generation of immune checkpoint inhibitors.
The company's most advanced program ICT01 is about to enter Ph2a as monotherapy against solid tumors and hematological cancers but also in combination with anti-PD1 and low dose IL-2.